Translocations involving IRF4 have a high specificity for cutaneous anaplastic large cell lymphoma. This FISH test identifies rearrangements involving the locus.
IRF4/DUSP22 rearrangement has been identified in up to 30% of ALK negative anaplastic large cell lymphomas. Positivity for the rearrangement is a positive prognostic sign.
This is an assay for non-heritable mutations. It does not raise issues of ethics or consent that are different from most other investigations ordered in the routine care of a patient.
Fluorescent in situ hybridisation (FISH) analysis, using probes to identify rearrangement involving IRF4/DUSP22.
Requesting the test
This test is usually requested by a haematologist or oncologist.
0.5 mL bone marrow in transport media, or 5-10 mL blood in lithium heparin.
To help ensure the quality of the test, a genetic test should be done with a dedicated sample whenever possible i.e. a sample collected specifically for that test rather than a sample that is used for multiple tests.
We recommend that the patient or another adult check the labelling of request forms and sample tubes.
Up to 4 weeks.
Up to $255.
If more information is required, the requesting clinician can call our laboratory on (07) 3377 8573.
This test is not rebated by Medicare. The laboratory assumes that the patient or client has provided informed financial consent for the test.